CSL Limited (CSL.AX)
| Previous close | 272.62 |
| Open | 270.13 |
| Bid | 271.92 x 13700 |
| Ask | 271.94 x 21700 |
| Day's range | 270.01 - 272.89 |
| 52-week range | 228.65 - 312.99 |
| Volume | |
| Avg. volume | 705,380 |
| Market cap | 131.44B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 34.39 |
| EPS (TTM) | 7.91 |
| Earnings date | 13 Feb 2024 |
| Forward dividend & yield | 3.81 (1.40%) |
| Ex-dividend date | 11 Mar 2024 |
| 1y target est | 306.79 |
Simply Wall St.CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...
Insider Monkey10 Best Long Term ASX Stocks To Invest In
In this piece, we will take a look at the ten best long term ASX stocks to invest in. If you want to skip our overview of the Australian stock market, then you can take a look at the 5 Best Long Term ASX Stocks To Invest In. Australia is one of the most prosperous […]
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.2 Ferinject has now received marketing authorization
